Bristol’s Breast Cancer Treatment Ixempra Gets FDA Nod
This article was originally published in The Pink Sheet Daily
Executive Summary
Ixempra, part of a new class of antineoplastic chemotherapy agents, is approved as both a monotherapy and in combination with capecitabine.
You may also be interested in...
Bristol’s Goal: 2 New Biologics/Year In Clinic – R&D Chief
Bristol-Myers Squibb’s R&D team plans to boost discovery output by 50 percent with only a modest increase in spending over three years, exec says.
Bristol’s Goal: 2 New Biologics/Year In Clinic – R&D Chief
Bristol-Myers Squibb’s R&D team plans to boost discovery output by 50 percent with only a modest increase in spending over three years, exec says.
Roche Backs Out Of Kosan Epothilone Deal
Kosan is “actively seeking” a new partner to begin Phase II trial for KOS-1584 after Roche unexpectedly terminates five-year collaboration.